IF Nav-Gal (galacto-conjugated navitoclax prodrug, estimated 50 mg/kg oral gavage, 3×/week intermittent dosing adapted from tumor-model protocols) is administered to aged (22–24-month-old) C57BL/6 male and female mice for 12 weeks,

THEN Nav-Gal will:

1. Clear senescent cells with efficacy equivalent to or exceeding free navitoclax (≥40% reduction in p16^Ink4a^, p21, and SA-β-gal+ cells in liver, kidney, skeletal muscle, and visceral fat),
2. Reverse frailty indices (≥15% improvement in grip strength and treadmill endurance vs. vehicle),
3. Maintain circulating platelet counts within ≤10% of baseline — contrasting with the ≥50% platelet depletion expected at therapeutic doses of free navitoclax —

BECAUSE the following causal chain operates in aged, but not young, tissue:

1. Age-related lysosomal dysfunction in senescent cells elevates GLB1 activity far above the baseline present in platelets or non-senescent tissue. Senescent cells accumulate enlarged, dysfunctional lysosomes with markedly elevated lysosomal β-galactosidase (GLB1) activity — the very biomarker that defines the SA-β-gal assay — and this elevation is substantially greater in replicatively aged senescent cells than in acutely therapy-induced senescent cells, making aged tissue a potentially superior substrate for Nav-Gal activation. (Lysosomal GLB1 overexpression drives SA-β-gal)[https://doi.org/10.1111/acel.13142]

2. Nav-Gal is selectively cleaved by GLB1 inside senescent lysosomes to release free navitoclax intracellularly. The acetylated galactose moiety on Nav-Gal masks navitoclax's BH3-binding pharmacophore, rendering it biologically inert in circulation; GLB1-mediated hydrolysis within senescent cell lysosomes restores full Bcl-2/Bcl-xL inhibitory activity locally. (Nav-Gal is a GLB1-dependent senolytic prodrug with broad activity)[https://doi.org/10.1111/acel.13142]

3. Intracellularly released navitoclax displaces pro-apoptotic BH3-only proteins from Bcl-xL and Bcl-2, triggering intrinsic apoptosis specifically within the GLB1-high senescent cell. The mechanistic requirement for high intracellular GLB1 creates a selectivity window: senescent cells die, non-senescent cells are spared. (ABT-263 markedly reduced SA-β-Gal–positive cells via BCL-XL–BAX interference)[https://doi.org/10.1002/1878-0261.12761]

4. Platelets, whose survival depends on Bcl-xL but which lack elevated GLB1 activity, are not exposed to sufficient free navitoclax to trigger apoptosis. Free navitoclax causes ~88% thrombocytopenia; Nav-Gal does not cause thrombocytopenia at equivalent therapeutic doses in tumor-bearing mice, because the prodrug is not activated in the platelet compartment. (Nav-Gal synthesized with galacto-conjugation to reduce platelet toxicity and increase specificity)[https://doi.org/10.1111/acel.13142] [SPECULATIVE extension: this platelet-sparing holds in the aged, non-tumor context where age-related senescent cells — not tumor stroma — are the target; direct evidence...

SENS category: GlycoSENS

Key references: • doi.org/10.1111/acel.13142] • doi.org/10.1002/1878-0261.12761] • doi.org/10.1038/s41422-020-0314-9] • doi.org/10.1016/j.ebiom.2017.04.013] • doi.org/10.1111/acel.13133]